Earnings ·
Gyre Therapeutics reported Q2 2026 revenue of $29.1 million and affirmed full-year guidance of $100.5 to $111.0 million
GYREGyre Therapeutics, Inc.
Gyre Therapeutics reported Q2 2026 revenue of $29.1 million and affirmed full-year guidance of $100.5 to $111.0 million. The company closed its all-stock acquisition of Cullgen in May for approximately $300 million, appointing Dr. Ying Luo as CEO and integrating a targeted protein degrader pipeline. Q2 revenue included $28.0 million from ETUARY sales, offset by the expiration of an Astella collaboration. GAAP basic EPS was $(0.12) with a net loss of $14.3 million. The company holds $103.2 million in cash and received NDA acceptance for F351 in China. Gyre Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing small-molecule therapeutics for organ fibrosis and inflammatory diseases.